LUNAC Therapeutics Overview

  • Founded
  • 2018

Founded
  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $5.91M

  • Investors
  • 8

LUNAC Therapeutics General Information

Description

Developer of advanced oral anticoagulant drugs designed to treat and prevent life-threatening thrombotic events. The company's drugs help to minimize the bleeding risk in patients, enabling healthcare providers to handle high-risk patients with safe dose escalation.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Nexus, Discovery Way
  • Yorks
  • Leeds LS2 3AA
  • England, United Kingdom

LUNAC Therapeutics Timeline

2019202020212022
Date FoundedFinancing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LUNAC Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC 13-May-2021 $5.91M 000.00 Completed Startup
5. Grant 01-Jun-2020 00000 0000 Completed Startup
4. Early Stage VC 06-May-2020 00.000 0000 0000 Completed Startup
3. Grant 02-Dec-2019 00.000 00.000 Completed Startup
2. Early Stage VC (Series A) 14-Nov-2019 $7.06M $7.06M 000.00 Completed Startup
1. Grant 01-Sep-2019 $1.96M Completed Startup
To view LUNAC Therapeutics’s complete valuation and funding history, request access »

LUNAC Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000 00.000000 000.00 000.00 00 000.00 00.000
To view LUNAC Therapeutics’s complete cap table history, request access »

LUNAC Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of advanced oral anticoagulant drugs designed to treat and prevent life-threatening thrombotic events. The com
Drug Discovery
Leeds, United Kingdom
000.00
0000000000 0 000.00

00000

ommodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fu
0000 000000000
Leiden, Netherlands
00 As of 0000
000.00
000000000000 000.00

000000

uip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum d
0000 000000000
Rockville, MD
00 As of 0000
0000
0000 0000-00-00
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

LUNAC Therapeutics Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
VarmX Venture Capital-Backed Leiden, Netherlands 00 000.00 000000000000 000.00
000000000 00000000 Venture Capital-Backed Rockville, MD 00 0000 00000000000 0000
You’re viewing 2 of 2 competitors. Get the full list »

LUNAC Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Julian Howell MD Co-Chief Executive Officer
Helen Philippou Scientific Co-Founder & Board Member
Richard Foster Scientific Co-Founder
Richard Brooks Head of Finance
You’re viewing 4 of 5 executive team members. Get the full list »

LUNAC Therapeutics Board Members (6)

Name Representing Role Since
Helen Philippou LUNAC Therapeutics Scientific Co-Founder & Board Member 000 0000
Mary Canning Ph.D Epidarex Capital Board Member 000 0000
Mervyn Turner Ph.D Self Chairman 000 0000
Peter Finan Ph.D Epidarex Capital Board Member 000 0000
Sarah Jarmin LUNAC Therapeutics Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

LUNAC Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Future Fund Government Minority 000 0000 000000 0
Mercia Asset Management Venture Capital Minority 000 0000 000000 0
Northern Powerhouse Investment Fund Lender/Debt Provider Minority 000 0000 000000 0
UK Government's Biomedical Catalyst funding Government 000 0000 000000 0
Caribou Property Ltd Corporation Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »